Robert J. Motzer

Featured in: Favicon

nature.com Favicon

wiley.com

jamanetwork.com Favicon

nejm.org

medscape.com Favicon

cell.com

thelancet.com Favicon

healio.com Favicon

futuremedicine.com Favicon

cancernetwork.com + 6 more

Articles

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial | Journal of Clinical Oncology

Sep 20, 2024 | brnw.ch | Robert J. Motzer |Axel Bex |Paul Russo

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Future Management of nccRCC

Apr 2, 2024 | targetedonc.com | Robert J. Motzer

2 Commerce Drive Cranbury, NJ 08512
Quality of Life Preservation

Mar 26, 2024 | targetedonc.com | Robert J. Motzer

Dr. Motzer shares his viewpoint on quality-of-life preservation observed with different regimens for nccRCC patients.
Risk/Benefits of Managing AEs with Combination Therapy

Mar 26, 2024 | targetedonc.com | Robert J. Motzer

Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.
Efficacy of Combination vs Single Agent Therapy

Mar 19, 2024 | targetedonc.com | Robert J. Motzer

2 Commerce Drive Cranbury, NJ 08512
Efficacy and Safety and Emerging Combinations

Mar 12, 2024 | targetedonc.com | Robert J. Motzer

Dr. Motzer provides his perspective on emerging efficacy and safety data updates from KEYNOTE-B61, and Nivolumab+Cabozantinib, evaluating combination regimens in nccRCC.
Efficacy and safety of KEYNOTE-427

Mar 12, 2024 | targetedonc.com | Robert J. Motzer

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Initial Impression of Case

Mar 5, 2024 | targetedonc.com | Robert J. Motzer

2 Commerce Drive Cranbury, NJ 08512
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Jan 16, 2024 | brnw.ch | Robert J. Motzer |Thomas Powles |Thomas Hutson

Introduction At the primary analysis point of the phase III open-label, CLEAR study (Study 307/KEYNOTE-581), with a median survival follow-up of 26.6 months, lenvatinib plus pembrolizumab showed superior efficacy versus sunitinib in the first-line treatment of patients with advanced renal cell carcinoma (aRCC).1 Lenvatinib plus pembrolizumab showed significant improvements versus sunitinib in progression-free survival (PFS: final analysis; hazard ratio [HR], 0.39 [95% CI, 0.32 to 0.49]; P <...
Future Perspectives in the Treatment of Advanced RCC

Nov 16, 2023 | onclive.com | Robert J. Motzer |Elizabeth R. Plimack

Future Perspectives in the Treatment of Advanced RCCOncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.